ClinicalTrials.gg
Active, not recruitingNCT05719116TREPPUpdated Sep 24, 2025

A Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders

An interventional study of Physical exercise in Psychosis, sponsored by Solli Distriktspsykiatriske Senter. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Psychotic Disorders with a site in Norway — 6 open to participants now, 7 under way, none of them phase 3. Psychotic Disorders · Norway.

Planned enrollment
16th of 20
40 · median 87
Started
2022
the only one that year
No phase
12 of 26
5 open now
Registered
20th of 26
by date
Lead sponsor
1 of 26
Solli Distriktspsykiatriske Senter

Among the 26 studies in Psychotic Disorders with a site in Norway, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2022, is one of 12 with no phase, and was the 20th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 26 studies in Psychotic Disorders with a site in Norway are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psychotic Disorders with a site in Norway, or all of them as a file.
02

Study summary

The study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders. The feasibility of the protocol will be investigated, in addition to the participants subjective experience with the participation.

Read the detailed description

The aim of this study is to investigate the feasibility of a 16 week physical exercise intervention combining strenght and aerobic training in group for patients with psychotic disorders. In addition, the feasibility of the test protocol and participants subjective experience with the intervention will be investigated.

Research shows positive effects of physical exercise for patients with psychotic disorders regarding maximal aerob training, maximal muscle strength, physical, cognitive and social functioning, and symptom levels. Effects and the degree of feasibility of physical exercise for patients with psychotic disorders are amplified by regarding their preferences and needs, and if they experience support and guidance during the intervention. Earlier studies have focused mostly on either strength og endurance training, or combined interventions of moderate intensity. We now want to investigate the feasibility of an invidually adjusted combined program of high intensity.

After the intervention, participants will be interviewed about their experience with participating.

03

Conditions studied

  • Psychosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants with psychotic disorder:

Inclusion Criteria:

  • Signed
  • Diagnosed with psychotic disorder
  • Physically able to participate in physical exercise
  • Is a patient at Solli DPS
  • Motivated for participating in physical exercise

Exclusion Criteria:

  • Physical conditions precluding the participant from the physical testing/training
  • Mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder

Participants with psychiatric disorder, but no psychotic disorder:

Inclusion Criteria:

  • Signed informed consent
  • Diagnosed with psychiatric disorder, but not a psychotic disorder
  • Physically able to participate in physical exercise
  • Is a patient at Solli DPS
  • Motivated for participating in physical exercise

Exclusion Criteria:

  • Physical conditions precluding the participant from the physical testing/training
  • Mental state that hinders participation, such as ongoing suicidality, substance abuse or brain organic disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Physical exercise for participants with psychotic disorder

    Participants with a psychotic disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.

    Behavioral: Physical exercise

  • Active comparator
    Physical exercise for participants with psychiatric disorder, but not psychotic disorder

    Participants with a psychiatric disorder will exercise in a group supervised by a physiotherapist for 16 weeks, three times a week.

    Behavioral: Physical exercise

Interventions

  • BehavioralPhysical exercise

    The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.

06

What researchers measure

Primary outcomes

  1. Feasibility of the intervention program

    How many participants completed the physical training intervention.

    Time frame: After 16 weeks of intervention

Secondary outcomes

  1. Aerobic capasity: Ekblom Bak submaximal ergometer cycle test

    Estimating Vo2max

    Time frame: At week 0 and 16

  2. Aerobic capasity: 4 x 4 interval for estimating VO2max

    Standarised 4x4 interval training for estimating VO2max with the smartphone app My Workout GO

    Time frame: At week 0 and 16

  3. Strength: 1 RM test of bench press

    Maximal test of strenght of upper body

    Time frame: At week 0 and 16

  4. Strenght: 1 RM test of squat

    Maximal test of lower body musculature

    Time frame: At week 0 and 16

  5. Psychotic symptoms: The Positive and Negative Syndrome Scale

    For the participants with psychotic disorders only. A measure of positive and negative psychotic symptoms. Each item is scored on a scale from 1-7 with a higher score indicating higher symptom level.

    Time frame: At week 0 and 16

  6. Depression symptoms: The Calgary Depression Scale for Schizophrenia

    A measure of depressive symptoms. Each item is scored on a scale from 0-3 with a higher score indicating higher symptom level.

    Time frame: At week 0 and 16

  7. Anxiety symptoms: GAD-7

    A measure of anxiety symptoms. This is a 7-item self-report questionnaire where participants rate on a scale from 0 (not at all sure) to 3 (nearly every day). A higher score indicates greater symptom severity.

    Time frame: At week 0 and 16

  8. Quality of life: SF-12

    A measure of health related quality of life. The items is scored after variying categories such as "yes" and "no", and "How much time during the past 4 weeks...".

    Time frame: At week 0 and 16

Other outcomes

  1. In depth interview

    A semi structured interview for asking the participants about their experience with the intervention

    Time frame: After 16 weeks of intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — We plan to publish our results in peer-reviewed journals.

Supporting information: Study protocol, Statistical analysis plan

Time frame: We plan to publish the study protocol. The statistical analysis plan will be available in published articles.

Access criteria: After data collection has been completed, data can be available upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 49 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2022
First posted
Feb 8, 2023
StartActual
Nov 23, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05719116
Lead sponsor
Solli Distriktspsykiatriske Senter
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Nov 23, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 24, 2025

Study contacts

Kristine Sirevåg
principal investigator · Solli DPS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion